Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.57 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1488338 | 1.00 | MAP2K1 (0.57) | MAP2K1MAP2K2CA2 | |
| Hydrochloric Acid SCHEMBL29413572 | 0.99 | MAP2K1 (0.56) | MAP2K1MAP2K2CA2 | |
| Hydrochloric Acid SCHEMBL1488399 | 0.99 | MAP2K1 (0.56) | MAP2K1MAP2K2CA2 | |
| SCHEMBL3849678 | 0.86 | MAP2K1 (0.47) | MAP2K1MAP2K2 | |
| SCHEMBL1488923 | 0.81 | MAP2K1 (0.45) | MAP2K1MAP2K2 | |
| SCHEMBL1488089 | 0.81 | MAP2K1 (0.64) | MAP2K1MAP2K2 | |
| SCHEMBL29413465 | 0.81 | MAP2K1 (0.64) | MAP2K1MAP2K2 | |
| Hydrochloric Acid SCHEMBL1488311 | 0.81 | MAP2K1 (0.63) | MAP2K1MAP2K2 | |
| Hydrochloric Acid SCHEMBL29413649 | 0.81 | MAP2K1 (0.63) | MAP2K1MAP2K2 | |
| SCHEMBL30221132 | 0.80 | MAP2K1 (0.46) | MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250100966-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | EXELIXIS INC (US) | 2025-03-27 | — | — | US | disclosed |
| US-11597699-B2 | MEK inhibitors and methods of their use | EXELIXIS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| CN-109053523-B | Azetidines as MEK inhibitors for the treatment of proliferative diseases | 埃克塞利希斯股份有限公司 | 2022-03-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250100966-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | BRAF, NRAS, KRAS | MAP2K1 53/4885MAP2K2 51/4885CA2 2853/4885 |
| US-11597699-B2 | MEK inhibitors and methods of their use | BRAF, NRAS, MAP3K20 | MAP2K1 52/4885MAP2K2 49/4885CA2 3134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.